Social Protection, and its directives are guided by international regulations, including ICH guidelines and those set by the World Health Organization (WHO).

Key roles of INVIMA include:

• Registration of Pharmaceutical Products: INVIMA evaluates and approves applications for drug registration, ensuring they meet safety, efficacy, and quality standards.
• Market Surveillance: INVIMA monitors the market for pharmaceutical products to safeguard public health, including adverse event reporting and pharmacovigilance.
• Regulatory Guidance: The agency provides comprehensive guidelines on compliance with statutory and regulatory requirements.
• Stakeholder Engagement: INVIMA collaborates with healthcare professionals, industry, and consumers to facilitate best practices in health products.

Understanding INVIMA’s mandate is essential for regulatory affairs professionals when preparing submissions, consulting on compliance, and negotiating approval processes. It is advisable to regularly review INVIMA’s publications and updates, as regulations can change, impacting submission strategies.

Step 2: Preparing the Dossier for Submission

Once you understand INVIMA’s landscape, the next critical step is to prepare the regulatory dossier for submission. This dossier must adhere to INVIMA’s guidelines and include a comprehensive documentation package. Here are important components to consider:

1. Common Technical Document (CTD) Format: The dossier should be structured according to the CTD format, which is internationally recognized. It consists of five modules:

• Module 1: Administrative Information and Prescribing Information
• Module 2: Summaries of Quality, Nonclinical, and Clinical Data
• Module 3: Quality (Chemistry, Manufacturing, and Controls) Information
• Module 4: Nonclinical Study Reports
• Module 5: Clinical Study Reports

2. GMP Compliance: Ensure that all manufacturing sites comply with Good Manufacturing Practices (GMP). Documentation verifying compliance is vital to the approval process.

3. Clinical Trial Data: If applicable, include evidence of clinical trials conducted under good clinical practice (GCP) guidelines. This data should be presented clearly and comprehensively.

4. Labels and Packaging Information: Provide samples of the proposed labels and packaging, which must conform to INVIMA’s regulations regarding information on indications, dosage, and risks.

Before submission, have the regulatory dossier reviewed and compiled by a regulatory writer or regulatory executive with relevant expertise. Thorough documentation can mitigate delays during the review phase.

Step 3: Understanding Regulatory Fees Associated with Submission

Rumors abound about unexpected costs when navigating the pharmaceutical regulatory landscape. Understanding the structure of regulatory fees is crucial for budgeting throughout the submission process. INVIMA has a specific fee schedule for various functions, and these can vary based on the nature of the product being submitted. Key points include:

1. Submission Fees: Fees are applicable at the time of submission for the registration of pharmaceuticals and can vary significantly depending on whether the product is a new drug, a generic, or another category of pharmaceutical product. Make sure to check the official INVIMA site for the most updated fee schedule.

2. Inspection Fees: In instances where INVIMA requires a physical inspection of manufacturing facilities, fees may apply and should be included in budgetary considerations.

3. Annual Fees: Once a product is approved, annual fees may be levied for market authorization maintenance. Familiarity with these fees ensures financial planning aligns with operational timelines.

Maintaining open communication with INVIMA is essential for clarity regarding applicable fees. Engaging financial or regulatory consultants familiar with INVIMA’s policies can also be beneficial.

Step 4: Submission Process and Review Timeline

The submission process is where effective communication and clear documentation become imperative. After preparation of the dossier and understanding the associated fees, it is time to submit your application. The submission is electronic and must be completed via the official INVIMA platform. Below are key steps in the submission process:

1. Online Submission: Use INVIMA’s electronic system to submit the application. Create an account if you don’t have one. Follow INVIMA’s detailed guidelines for filling out forms and uploading documents correctly.

2. Application Verification: Upon submission, INVIMA will conduct a preliminary check to ensure all necessary documents have been submitted in line with their guidelines. This initial review typically takes around 15 days. Be prepared for the possibility of being asked for additional documentation or clarification.

3. Scientific Evaluation: After passing the initial verification, the submitted dossier undergoes a detailed scientific evaluation, typically lasting between 180 to 210 days. During this time, INVIMA reviews all aspects of the dossier, including quality, efficacy, and safety.

4. Interaction with INVIMA: INVIMA may issue requests for additional information (RFI) during the review process. Engage promptly with these requests to avoid extended delays in approval. A dedicated regulatory executive can facilitate communication effectively during this phase.

Upon successful completion of the review, INVIMA will issue a Certificate of Marketing Authorization (CMA) if the product meets the necessary requirements. While the submission process can be lengthy, clear documentation and active communication can help ease the pathway to approval.

Step 5: Post-Approval Commitments and Pharmacovigilance

Once the product has received regulatory approval from INVIMA, the journey for regulatory affairs professionals doesn’t end. It is critical to adhere to post-approval commitments, especially in terms of ongoing pharmacovigilance and compliance with further regulatory requirements.

1. Pharmacovigilance Obligations: Regulatory affairs teams must establish processes for monitoring the safety of the product once it is on the market. This includes documenting adverse reactions, maintaining a risk management system, and reporting findings to INVIMA as required by law. Failure to monitor and report could result in sanctions or revocation of marketing authorization.

2. Periodic Safety Update Reports (PSURs): INVIMA may require periodic reporting on the safety profile of the product, which may include mandatory PSURs that provide updated information on known risks, potential risks, and new safety data.

3. Renewal of Marketing Authorization: Marketing authorizations are time-limited, and it’s vital to start preparing for renewals well in advance of expiration. Additionally, any changes to the product (such as formulation or labeling changes) must be communicated and approved by INVIMA. Involvement of regulatory executives is vital for these processes.

Staying compliant with post-approval obligations not only ensures the continued availability of the product in the market but also safeguards public health, upholding the trust placed in pharmaceutical companies by regulatory authorities.

Conclusion

Navigating the pharmaceutical regulatory landscape in Colombia through INVIMA requires a comprehensive understanding of the regulatory fees, submission timelines, and post-approval commitments. By meticulously preparing the regulatory dossier, understanding the financial implications of the filing process, and adhering to compliance measures, regulatory affairs professionals can position their organizations for success in this crucial market. Continued engagement with INVIMA, preparation for possible challenges, and proactive monitoring of evolving regulatory landscapes will further enhance the chances of achieving and maintaining successful product approvals in Colombia.

For further information on INVIMA’s specific regulations and regulatory updates, visit the official INVIMA website.